Deliver Your News to the World

BiomedReports: Speculative Sequenom Shares (Nasdaq:SQNM) Lift Off


Pasadena, CA - 06/09/09 - BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has initiated a full report on the companies in the health care sector that moved markets on Tuesday.

Once again, the market found itself in a tug of war as investors tried to find some good news-- and for some BioMed investors the day became a matter of finding out what the good news was to begin with.

Shares of Sequenom, Inc.(Nasdaq:SQNM) started to rise mid-morning and they haven’t stopped. The question is, why?

A mid-day glance at our exploding e-mail box told us that traders were scratching their heads, since no hard news items could be credited with the rise of the badly beaten Sequenom shares.

After hours on 06/09/09, as of the time of this article, SQNM shares were up +1.95 (58.21%) and climbing to $5.30.

Investors are invited to read our full report on the healthcare companies which moved Tuesday’s markets- including Sequenom- at BioMedReports.Com.

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

Disclosure: No positions.


About BiomedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 FDA Approval
 FDA Decisions
 Clinical Trials

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.